According to Zacks, “Post a promising third quarter by Hill-Rom, we are upbeat about the company to remain on a solid growth trajectory over the near term. The company’s year-over-year outcome was impressive along with record level of gross margin. Based on several positive catalysts, we expect the company to expand geographically in the coming quarters. Notably, in the last reported quarter, Hill-Rom posted strong growth in both Asia-Pacific and the U.S. While we remain impressed with the company’s increased bottom-line guidance for fiscal 2016, the revenue guidance was quite discouraging. Moreover, Hill-Rom’s persistent poor performance in the International front, especially in the Middle East and Latin America keeps us concerned. Unfortunately no near term improvement can be expected in the existing capital crunch condition that eventually led to economic and political downturns in these economies.”
Other equities analysts also recently issued research reports about the stock. KeyCorp reissued a buy rating and set a $59.00 target price on shares of Hill-Rom Holdings in a research note on Thursday, June 23rd. Morgan Stanley raised shares of Hill-Rom Holdings from an equal weight rating to an overweight rating and lifted their target price for the stock from $54.00 to $62.00 in a research note on Thursday, June 16th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Hill-Rom Holdings presently has a consensus rating of Buy and a consensus price target of $61.83.
Hill-Rom Holdings (NYSE:HRC) opened at 60.84 on Tuesday. The stock’s 50 day moving average is $58.55 and its 200-day moving average is $52.33. Hill-Rom Holdings has a 1-year low of $42.99 and a 1-year high of $60.92. The firm has a market capitalization of $3.98 billion, a P/E ratio of 62.66 and a beta of 1.06.
Hill-Rom Holdings (NYSE:HRC) last announced its earnings results on Thursday, August 4th. The medical technology company reported $0.81 earnings per share for the quarter, topping analysts’ consensus estimates of $0.76 by $0.05. Hill-Rom Holdings had a net margin of 2.47% and a return on equity of 16.62%. The business earned $655.40 million during the quarter, compared to the consensus estimate of $647.75 million. During the same quarter last year, the firm earned $0.62 earnings per share. Hill-Rom Holdings’s quarterly revenue was up 38.1% on a year-over-year basis. Analysts forecast that Hill-Rom Holdings will post $3.33 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 16th will be given a dividend of $0.17 per share. This represents a $0.68 annualized dividend and a dividend yield of 1.12%. The ex-dividend date of this dividend is Wednesday, September 14th. Hill-Rom Holdings’s payout ratio is presently 73.91%.
Several large investors have recently bought and sold shares of HRC. BlackRock Inc. increased its stake in Hill-Rom Holdings by 18.5% in the first quarter. BlackRock Inc. now owns 24,859 shares of the medical technology company’s stock valued at $1,250,000 after buying an additional 3,877 shares during the last quarter. Franklin Resources Inc. increased its stake in Hill-Rom Holdings by 4.0% in the first quarter. Franklin Resources Inc. now owns 1,573,700 shares of the medical technology company’s stock valued at $79,157,000 after buying an additional 61,000 shares during the last quarter. Prudential Financial Inc. increased its stake in Hill-Rom Holdings by 42.6% in the first quarter. Prudential Financial Inc. now owns 584,054 shares of the medical technology company’s stock valued at $29,377,000 after buying an additional 174,557 shares during the last quarter. Teachers Advisors Inc. increased its stake in Hill-Rom Holdings by 9.2% in the first quarter. Teachers Advisors Inc. now owns 323,425 shares of the medical technology company’s stock valued at $16,268,000 after buying an additional 27,243 shares during the last quarter. Finally, TIAA CREF Investment Management LLC increased its stake in Hill-Rom Holdings by 107.2% in the first quarter. TIAA CREF Investment Management LLC now owns 273,081 shares of the medical technology company’s stock valued at $13,736,000 after buying an additional 141,282 shares during the last quarter. 83.11% of the stock is owned by institutional investors.
Hill-Rom Holdings Company Profile
Hill-Rom Holdings, Inc is a medical technology company. The Company offers patient care solutions that improve clinical and economic outcomes in advancing mobility, wound care and prevention, clinical workflow, surgical safety and efficiency, and respiratory health areas. Its segments include North America, Surgical and Respiratory Care, International and Welch Allyn.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hill-Rom Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.